Amgen's Q1 results were solid financially, with record revenues and EPS growth. However, the focus of the earnings call was on the impact of Healthcare Reform, which is expected to affect the company significantly. The management provided an in-depth analysis of the short-term financial implications, but the true impact remains uncertain due to the complex nature of the changes. The stock will likely face pressure in the short term as investors digest the potential ramifications. [-1]